Male Pattern Hair Loss: Causes, Stages, and Evidence-Based Treatments

How DHT Drives Androgenetic Alopecia

Dihydrotestosterone, a potent androgen converted from testosterone by the enzyme 5-alpha reductase, is the central molecule behind male pattern hair loss. In genetically susceptible follicles, DHT binds to androgen receptors in the dermal papilla, triggering a shortening of the anagen (growth) phase and progressive miniaturization of terminal hairs into vellus-like fibers.

The genetic component is polygenic. A key susceptibility locus sits on the X chromosome within the androgen receptor gene, which is why maternal inheritance patterns are often cited 1. Genome-wide association studies have identified more than 200 additional loci on autosomes that contribute smaller effects 2. Not every man with elevated DHT loses hair. The difference lies in follicle-level receptor density and sensitivity, both of which are genetically programmed. Occipital and parietal follicles are typically resistant, which is why donor hair in transplant surgery retains its growth characteristics after relocation.

The miniaturization process is gradual. A single follicle may cycle through progressively shorter anagen phases over 10 to 15 years before producing only fine, unpigmented vellus hair. This is why early intervention, before the follicle stem cell niche is irreversibly depleted, matters so much clinically.

The Norwood-Hamilton Scale: Staging Hair Loss

The Norwood-Hamilton classification divides male pattern hair loss into seven stages, giving clinicians and patients a shared vocabulary for tracking progression. Stage I shows no significant recession. Stage VII represents the most advanced form, with only a narrow band of hair remaining along the sides and back of the scalp.

Most men first notice changes at stage II or III, which involves temporal recession with or without early vertex thinning. The distinction between stage IIIa (isolated frontal recession) and stage IIIv (vertex thinning with minimal frontal change) matters for treatment planning: vertex-predominant loss tends to respond better to topical minoxidil, while frontal recession often requires systemic DHT suppression 3. Staging also guides surgical candidacy. Transplant surgeons generally prefer to operate on patients whose loss has stabilized (usually after age 25 to 30) to avoid placing grafts in areas that will continue to thin.

A trichoscopy or phototrichogram can supplement Norwood staging by quantifying miniaturization ratios. A ratio above 20% miniaturized hairs in the frontal scalp is considered diagnostic for androgenetic alopecia 4.

Finasteride: The Oral Standard

Finasteride 1 mg daily remains the most studied oral treatment for male pattern hair loss. It inhibits type II 5-alpha reductase, reducing serum DHT by approximately 70% and scalp DHT by about 40% 5.

In the key two-year trial that led to FDA approval, 83% of men taking finasteride 1 mg maintained or increased hair count at the vertex, compared with 28% of men on placebo 6. The study also showed a mean increase of 107 hairs per 1-inch circle at the vertex. Five-year extension data confirmed durable benefit, though some attenuation occurred after year two 7.

Sexual side effects (decreased libido, erectile changes) occurred in 1.3% to 1.8% of finasteride users versus 0.7% to 1.3% on placebo across clinical trials 5. These resolved after discontinuation in the vast majority of cases. The concept of "post-finasteride syndrome," involving persistent sexual or neuropsychiatric symptoms, has been described in case series but has not been confirmed in controlled prospective studies 8. The American Hair Loss Association and multiple international guidelines still recommend finasteride as a first-line oral therapy.

Dr. Jerry Shapiro, a professor of dermatology at NYU Langone, has stated: "Finasteride remains the most effective single medical treatment for androgenetic alopecia in men, and the safety profile over 25 years of post-market surveillance is reassuring for the vast majority of patients" 3.

Dutasteride: A More Potent Alternative

Dutasteride inhibits both type I and type II 5-alpha reductase, lowering serum DHT by more than 90%. It is approved for androgenetic alopecia in South Korea and Japan (0.5 mg daily) but is used off-label for this indication in the United States.

A randomized controlled trial of 917 men compared dutasteride 0.5 mg to finasteride 1 mg over 24 weeks. Dutasteride produced significantly greater improvements in target-area hair count (an increase of 12.2 hairs/cm² vs. 4.7 hairs/cm² for finasteride, P<0.001) 9. The side-effect profile was comparable between the two drugs. Because of its longer half-life (approximately five weeks), dutasteride takes longer to wash out if a patient wants to discontinue.

Clinicians tend to reserve dutasteride for men who have had an incomplete response to finasteride after 12 months. Some prescribers use a "switch" strategy; others add dutasteride on alternating days. The 2019 British Association of Dermatologists guidelines list dutasteride as a second-line oral option for androgenetic alopecia 10.

Minoxidil: Topical and Low-Dose Oral

Topical minoxidil (5% for men) prolongs the anagen phase and increases follicular blood flow through potassium-channel opening. A 48-week trial showed that 5% minoxidil foam produced a mean change of +18.6 nonvellus hairs per cm² versus +12.7 for 2% solution 11. Response rates are highest at the vertex. Frontal efficacy is more modest but still measurable.

The main drawbacks of topical use are application-site irritation, the twice-daily regimen, and cosmetic concerns (greasy residue with solutions). These barriers have driven growing interest in low-dose oral minoxidil, typically 2.5 mg to 5 mg daily.

A retrospective cohort at Sinclair Dermatology (N=1,404) found that oral minoxidil 2.5 mg was well tolerated and produced clinically meaningful regrowth in 62% of male patients at 12 months, with hypertrichosis (unwanted body or facial hair) as the most common side effect at 15.1% 12. Cardiovascular side effects (peripheral edema, tachycardia) were rare at doses below 5 mg. The American Academy of Dermatology has not yet issued formal guidance on oral minoxidil for hair loss, but multiple expert consensus papers support its off-label use at low doses with appropriate cardiovascular screening 12.

Differentiating Male Pattern Hair Loss from Other Alopecias

Not all hair loss is androgenetic. Getting the diagnosis right determines whether DHT-blocking drugs are appropriate.

Telogen effluvium causes diffuse shedding, often 2 to 3 months after a triggering event such as surgery, high fever, crash dieting, or severe emotional stress. The classic presentation is handfuls of hair on the pillow or in the shower drain, without the patterned recession typical of androgenetic alopecia. A "positive hair pull test" (more than 10% of pulled hairs come out) supports the diagnosis. Telogen effluvium is self-limited in most cases, resolving within 6 to 9 months once the trigger is removed 13.

Female pattern hair loss shares a genetic and hormonal overlap with the male form but presents with diffuse thinning centered on the crown and a preserved frontal hairline. The Ludwig scale is used for staging. Topical minoxidil 2% or 5% and spironolactone (50 to 200 mg daily) are first-line treatments. Finasteride is generally avoided in premenopausal women due to teratogenicity risk 14.

Alopecia areata is an autoimmune condition targeting hair follicles, producing well-demarcated, smooth, round patches of hair loss. It can progress to alopecia totalis (complete scalp loss) or universalis (total body hair loss). The FDA approved baricitinib (Olumiant), a JAK inhibitor, for severe alopecia areata in 2022 after the BRAVE-AA1 trial (N=654) showed that 38.8% of patients achieved 80% or greater scalp coverage at 36 weeks on baricitinib 4 mg versus 6.2% on placebo 15. Ritlecitinib (Litfulo) received FDA approval for alopecia areata in 2023 for patients aged 12 and older.

Acne vulgaris frequently coexists with androgenetic alopecia in younger men because both conditions are androgen-driven. Isotretinoin treatment for severe acne can sometimes trigger telogen effluvium, creating a confusing clinical picture. A careful timeline history helps separate drug-induced shedding from early androgenetic alopecia.

Combination Therapy and Emerging Treatments

The S3 European Dermatology Forum guideline on androgenetic alopecia recommends combining finasteride and minoxidil for patients who want maximal medical therapy before considering surgery 16. The rationale is straightforward: finasteride reduces the hormonal driver while minoxidil stimulates follicle activity through a separate mechanism. Small head-to-head studies suggest combination therapy outperforms either agent alone, though large randomized trials directly comparing monotherapy to combination regimens are still limited.

Platelet-rich plasma (PRP) involves concentrating a patient's own platelets and injecting them into the scalp. A meta-analysis of 11 RCTs (N=483) found a pooled standardized mean difference of 1.03 (95% CI 0.55 to 1.52) favoring PRP over placebo for hair density 17. Protocols vary widely in platelet concentration, activation method, and injection intervals, which limits direct comparison across studies. Most dermatologists position PRP as an adjunct, not a standalone treatment.

Low-level laser therapy (LLLT) devices cleared by the FDA (as 510(k) devices, not through the drug approval pathway) include laser combs, helmets, and caps emitting 650 to 900 nm light. A 26-week RCT of a laser comb (N=110) showed a 19.8 hairs/cm² increase versus 2.8 hairs/cm² for sham 18. Compliance can be a barrier because devices require 10 to 30 minutes of use every other day.

Topical finasteride (typically 0.25% solution) is being developed to deliver DHT reduction at the scalp while minimizing systemic absorption. A phase II trial showed that topical finasteride 0.25% reduced scalp DHT to a degree comparable to oral finasteride 1 mg while producing roughly 50% less suppression of serum DHT 19. This may appeal to patients concerned about systemic side effects.

Dr. Antonella Tosti, professor of dermatology at the University of Miami, has noted: "We are entering an era where treatment can be genuinely personalized. The patient who cannot tolerate oral finasteride now has topical alternatives, low-dose oral minoxidil, and PRP as real clinical tools, not just theoretical options."

Hair Transplantation: FUT vs. FUE

When medical therapy cannot restore adequate density, surgical hair restoration becomes the discussion. Two techniques dominate.

Follicular unit transplantation (FUT) removes a strip of donor scalp from the occiput, which is then dissected into individual follicular units under magnification. It yields high graft counts (up to 3,000 to 4,000 grafts per session) and has a linear scar as its main disadvantage.

Follicular unit extraction (FUE) harvests individual follicular units with a 0.8 to 1.0 mm punch. It avoids a linear scar, allows shorter hairstyles, and has a faster recovery. The trade-off is longer operative time and generally higher cost.

Both techniques achieve graft survival rates above 90% when performed by experienced surgeons 20. The choice between them depends on donor density, hair caliber, patient preference for postoperative styling, and how many grafts are needed. Patients should continue finasteride (or another medical therapy) after transplantation to protect native hair that was not transplanted.

When to Start Treatment

Early treatment preserves options. Once a follicle has spent enough cycles in a miniaturized state, the stem cell niche can become irreversibly depleted, making pharmacologic regrowth impossible. The 2017 European evidence-based S3 guideline gives a strong recommendation for starting finasteride or topical minoxidil at the first objective sign of progressive miniaturization 16.

A reasonable workup before starting treatment includes a clinical exam with dermoscopy, a review of family history, and baseline blood work (testosterone, thyroid function, ferritin, and CBC) to exclude mimics like thyroid dysfunction or iron deficiency contributing to hair shedding. For men under 21, discussing the risk-benefit profile of finasteride in the context of ongoing development is appropriate.

Treatment response should be assessed photographically at standardized intervals: baseline, 6 months, and 12 months. Expecting full regrowth is unrealistic; the goal for most patients is stopping progression and recovering partial density. Men who respond to medical therapy need to continue it indefinitely, because discontinuation leads to resumed hair loss within 6 to 12 months as DHT levels return to baseline.